Korean J Gastroenterol.  2014 Sep;64(3):133-141. 10.4166/kjg.2014.64.3.133.

Current Issues in Functional Dyspepsia

• Park JK
• Huh KC
• Shin CM
• Lee H
• Yoon YH
• Song KH
• Min BH
• Choi KD
• The Korean Society of Neurogastroenterology and Motility

• KMID: 2160654
• DOI: http://doi.org/10.4166/kjg.2014.64.3.133

Abstract

Functional dyspepsia is one of the most common gastrointestinal disorders encountered in clinical practice. Functional dyspepsia is currently defined by Rome III criteria as the chronic dyspeptic symptoms (postprandial fullness, early satiety, epigastric pain or burning) in the absence of underling structural or metabolic disease that readily explain the symptoms. According to the Rome III consensus, functional dyspepsia can be subdivided into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Although the Rome III criteria have been published more than 8 years ago, not much effort has been put into validating these criteria and direct scientific evidence supporting the validity of the subdividing functional dyspepsia into PDS and EPS are lacking. This article is intended to review the validity of the Rome III criteria on the subdivisions of functional dyspepsia, i.e. PDS and EPS. The impact of sleep disorder, Helicobacter pylori-associated dyspepsia, and the emerging drug therapies in functional dyspepsia will also be discussed in this article.

Keyword

Functional dyspepsia; Diagnosis; Sleep disorder; Helicobacter pylori

MeSH Terms

Anti-Anxiety Agents/therapeutic use
Diagnosis, Differential
Dyspepsia/complications/*diagnosis/drug therapy
Gastrointestinal Agents/therapeutic use
Helicobacter Infections/complications/diagnosis
Humans
Serotonin Receptor Agonists/therapeutic use
Severity of Illness Index
Sleep Wake Disorders/etiology
Anti-Anxiety Agents
Gastrointestinal Agents
Serotonin Receptor Agonists

Reference

References

1. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemo-graphy, and health impact. Dig Dis Sci. 1993; 38:1569–1580.

2. El-Serag HB, Talley NJ. Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther. 2003; 18:387–393.

3. Nyrén O, Lindberg G, Lindström E, Marké LA, Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics. 1992; 1:312–324.

4. Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology. 2009; 137:94–100.

5. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130:1466–1479.

6. Lee YY, Wahab N, Mustaffa N, et al. A Rome III survey of functional dyspepsia among the ethnic Malays in a primary care setting. BMC Gastroenterol. 2013; 13:84.

7. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. Gastroenterology. 2014; 146:932–940.e1.

8. Goldsmith G, Levin JS. Effect of sleep quality on symptoms of irritable bowel syndrome. Dig Dis Sci. 1993; 38:1809–1814.

9. Kusano M, Kouzu T, Kawano T, Ohara S. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. J Gastroenterol. 2008; 43:833–841.

10. Futagami S, Yamawaki H, Izumi N, et al. Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. J Gastroenterol Hepatol. 2013; 28:1314–1320.

11. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005; 129:1756–1780.

12. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012; 27:626–641.

13. Suzuki H, Matsuzaki J, Hibi T. What is the difference between Helicobacter pylori-associated dyspepsia and functional dyspepsia? J Neurogastroenterol Motil. 2011; 17:124–130.

14. Geeraerts B, Tack J. Functional dyspepsia: past, present, and future. J Gastroenterol. 2008; 43:251–255.

15. Abid S, Siddiqui S, Jafri W. Discriminant value of Rome III questionnaire in dyspeptic patients. Saudi J Gastroenterol. 2011; 17:129–133.

16. Vakil N, Talley N, van Zanten SV, et al. STARS I Study Group. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol. 2009; 7:756–761.

17. Kim ES, Lee BJ, Kim YS, Lee SI, Park H. Validation of Rome III criteria in the diagnosis of functional gastrointestinal disorders in Korean patients. Korean J Neurogastroenterol Motil. 2008; 14:39–44.

18. Song KH, Jung HK, Min BH, et al. Development and validation of the Korean Rome III questionnaire for diagnosis of functional gastrointestinal disorders. J Neurogastroenterol Motil. 2013; 19:509–515.

19. Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther. 2006; 23:923–936.

20. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology. 2006; 130:296–303.

21. Laheij RJ, De Koning RW, Horrevorts AM, et al. Predominant symptom behavior in patients with persistent dyspepsia during treatment. J Clin Gastroenterol. 2004; 38:490–495.

22. Piessevaux H, De Winter B, Louis E, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil. 2009; 21:378–388.

23. Castillo EJ, Camilleri M, Locke GR, et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol. 2004; 2:985–996.

24. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology. 2010; 138:1302–1311.

25. Min BH, Huh KC, Jung HK, et al. Functional Dyspepsia Study Group of Korean Society of Neurogastroenterology and Motility. Prevalence of uninvestigated dyspepsia and gastroesophageal reflux disease in Korea: a population-based study using the Rome III criteria. Dig Dis Sci. 2014. [Epub ahead of print].

26. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut. 1999; 45(Suppl 2):II37–II42.

27. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 2008; 8:43.

28. Park JM, Choi MG, Cho YK, et al. Functional gastrointestinal disorders diagnosed by Rome III questionnaire in Korea. J Neurogastroenterol Motil. 2011; 17:279–286.

29. Haag S, Senf W, Tagay S, et al. Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia? Neurogastroenterol Motil. 2010; 22:262–e79.

30. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and nonerosive reflux disease. Digestion. 2009; 79:65–72.

31. Ahmed AB, Matre K, Hausken T, Gregersen H, Gilja OH. Rome III subgroups of functional dyspepsia exhibit different characteristics of antral contractions measured by strain rate imaging: a pilot study. Ultraschall Med. 2012; 33:E233–E240.

32. Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-con-trol study. Clin Gastroenterol Hepatol. 2007; 5:1175–1183.

33. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocy-tosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009; 29:765–773.

34. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010; 105:1835–1842.

35. Walker MM, Aggarwal KR, Shim LS, et al. Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol. 2014; 29:474–479.

36. Oshima T, Nakajima S, Yokoyama T, et al. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet. 2010; 11:13.

37. Shimpuku M, Futagami S, Kawagoe T, et al. G-protein β3 subunit 825CC genotype is associated with postprandial distress syndrome with impaired gastric emptying and with the feeling of hun-ger in Japanese. Neurogastroenterol Motil. 2011; 23:1073–1080.

38. Park HY, Jahng JH, Lee YJ, Park HJ, Lee SI. Serotonin transporter gene and G-protein β3 C825T gene polymorphism in patients with functional dyspepsia and irritable bowel syndrome. Korean J Neurogastroenterol Motil. 2009; 15:58–64.

39. Kim HG, Lee KJ, Lim SG, Jung JY, Cho SW. G-protein beta3 subunit C825T polymorphism in patients with overlap syndrome of functional dyspepsia and irritable bowel syndrome. J Neurogastroenterol Motil. 2012; 18:205–210.

40. Park CS, Uhm JH. Polymorphisms of the serotonin transporter gene and G-protein β3 subunit gene in Korean children with irritable bowel syndrome and functional dyspepsia. Gut Liver. 2012; 6:223–228.

41. Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013; 10:187–194.

42. Miwa H, Ghoshal UC, Gonlachanvit S, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012; 18:150–168.

43. Hsu YC, Liou JM, Yang TH, et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol. 2011; 46:183–190.

44. Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol. 2010; 105:2626–2631.

45. Futagami S, Shimpuku M, Song JM, et al. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion. 2012; 86:114–121.

46. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med. 2011; 171:1929–1936.

47. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009; 21:272–280.

48. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012; 61:821–828.

49. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med. 2003; 65:528–533.

50. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey con-ducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003; 98:1487–1493.

51. Yi CH, Hu CT, Chen CL. Sleep dysfunction in patients with GERD: erosive versus nonerosive reflux disease. Am J Med Sci. 2007; 334:168–170.

52. Lacy BE, Everhart K, Crowell MD. Functional dyspepsia is associated with sleep disorders. Clin Gastroenterol Hepatol. 2011; 9:410–414.

53. Yamawaki H, Futagami S, Shimpuku M, et al. Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil. 2014; 20:104–112.

54. Lu CL, Chang SS, Wang SS, Chang FY, Lee SD. Silent peptic ulcer disease: frequency, factors leading to “silence,” and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc. 2004; 60:34–38.

55. Wang FW, Tu MS, Mar GY, et al. Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan. World J Gastroenterol. 2011; 17:1199–1203.

56. Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol. 2004; 39:97–103.

57. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med. 2008; 47:1077–1083.

58. Liu Y, Vosmaer GD, Tytgat GN, Xiao SD, Ten Kate FJ. Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. J Clin Pathol. 2005; 58:927–931.

59. Pike BL, Porter CK, Sorrell TJ, Riddle MS. Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis. Am J Gastroenterol. 2013; 108:1558–1563. quiz 1564.

60. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil. 2010; 16:30–34.

61. D'Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter. 2009; 14(Suppl 1):21–28.

62. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology. 2007; 132:2116–2130.

63. Lee KJ, Cha DY, Cheon SJ, Yeo M, Cho SW. Plasma ghrelin levels and their relationship with gastric emptying in patients with dys-motility-like functional dyspepsia. Digestion. 2009; 80:58–63.

64. Kawashima J, Ohno S, Sakurada T, et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol. 2009; 44:1046–1054.

65. Osawa H, Nakazato M, Date Y, et al. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab. 2005; 90:10–16.

66. Takamori K, Mizuta Y, Takeshima F, et al. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol. 2007; 41:477–483.

67. Akamizu T, Iwakura H, Ariyasu H, et al. FD Clinical Study Team. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol. 2008; 158:491–498.

68. Saito Y, Suzuki H, Tsugawa H, et al. Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in Helicobacter pylori-infected mice. Gastroenterology. 2011; 140:189–198.

69. Suzuki H, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol. 2011; 26(Suppl 3):42–45.

70. Sugano K. Should we still subcategorize Helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil. 2011; 17:366–371.

71. Lee H, Jung HK, Huh KC. Functional Dyspepsia Study Group in the Korean Society of Neurogastroenterology and Motility. Current status of functional dyspepsia in Korea. Korean J Intern Med. 2014; 29:156–165.

72. Jee SR, Jung HK, Min BH, et al. Korean Society of Neurogastroenterology and Motility. Guidelines for the treatment of functional dyspepsia. Korean J Gastroenterol. 2011; 57:67–81.

73. Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther. 2002; 16:959–967.

74. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A place-bo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006; 354:832–840.

75. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, dou-ble-blind, placebo-controlled trials. Gut. 2008; 57:740–746.

76. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008; 103:1906–1919.

77. Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut. 2005; 54:455–460.

78. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol. 2008; 8:690–696.

79. McCallum RW, Lembo A, Esfandyari T, et al. TZP-102 Phase 2b Study Group. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013; 25:e705–e717.

80. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998; 115:1346–1352.

81. Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012; 10:1239–1245.

82. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009; 104:2779–2787.

83. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012; 24:540–e251.

84. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia: 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010; 22:618–e173.

85. Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol. 2005; 40:1036–1042.

86. van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the anti-depressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008; 6:746–752. quiz 718.

87. Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of ami-triptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011; 34:638–648.

88. Read NW, Abitbol JL, Bardhan KD, Whorwell PJ, Fraitag B. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut. 1997; 41:664–668.

89. Talley NJ, Choung RS, Camilleri M, Dierkhising RA, Zinsmeister AR. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther. 2008; 27:1122–1131.